{"id":"tm-buprenorphine","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Headache"},{"rate":"10-20","effect":"Constipation"},{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Insomnia"},{"rate":"5-10","effect":"Sweating"},{"rate":"<1","effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL2368861","moleculeType":"Small molecule","molecularWeight":"504.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine acts as a partial agonist at the mu-opioid receptor, meaning it produces submaximal effects compared to full agonists like morphine. This partial agonism provides analgesia and reduces withdrawal symptoms in opioid-dependent patients while having a built-in safety profile due to a ceiling effect on respiratory depression. The high receptor binding affinity also makes it difficult for other opioids to displace it, reducing the risk of overdose when combined with other substances.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:56.488Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (maintenance treatment)"},{"name":"Moderate to severe pain"}]},"trialDetails":[{"nctId":"NCT04995029","phase":"PHASE4","title":"Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2021-10-26","conditions":"Moderate to Severe Opioid-use Disorder","enrollment":785},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT03993392","phase":"PHASE4","title":"SUBLOCADE Rapid Initiation Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-08-29","conditions":"Opioid-use Disorder","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":166,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["suboxone","subutex","belbuca","zubsolv","bunavail"],"phase":"marketed","status":"active","brandName":"TM buprenorphine","genericName":"TM buprenorphine","companyName":"Indivior Inc.","companyId":"indivior-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TM buprenorphine is a small molecule that acts as a mu opioid receptor agonist. It is used to treat moderate to severe opioid-use disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}